Biora Therapeutics Collaborates With Large Pharmaceutical Company To Test BioJet Systemic Oral Delivery Platform's Ability To Achieve Bioavailability Through Oral Delivery Of The Undisclosed Collaborator's Molecules To The Small Intestine In Animal Models
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics has entered into a collaboration with an undisclosed large pharmaceutical company to test the BioJet Systemic Oral Delivery Platform. The platform's effectiveness in achieving bioavailability through oral delivery of the collaborator's molecules to the small intestine will be evaluated using animal models.
December 11, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biora Therapeutics' collaboration with a large pharmaceutical company to test its BioJet platform could potentially validate the technology and lead to future partnerships or licensing deals.
The collaboration with a large pharmaceutical company is a significant validation of Biora Therapeutics' BioJet platform. If the tests are successful, it could lead to increased investor confidence and potential for future deals, which may have a positive impact on BIOR's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100